Publications by authors named "Graziela Schmitt Becker"
Propionic and methylmalonic acidemias (PAcidemia and MMAcidemia, respectively) are genetic disorders characterized by acute metabolic decompensation and neurological complications. L-carnitine (LC) is effective in reducing toxic metabolites that are related to the pathophysiology of these diseases. Therefore we investigated biomarkers of inflammation (cytokines and C-reactive protein (CRP)), neurodegeneration (BDNF, NCAM-1 and cathepsin-D) and biomolecules oxidation (sulfhydryl content and thiobarbituric acid-reactive species (TBARS)), as well as carnitine concentrations in untreated patients with PAcidemia and MMAcidemia, in patients under treatment with LC and a protein-restricted diet for until 2 years and in patients under the same treatment for more than 2 years.
View Article and Find Full Text PDFArticle Synopsis
- Propionic and methylmalonic acidemias are serious genetic disorders in newborns that cause dangerous metabolic crises, necessitating swift treatment for survival.
- A study found that a low-protein diet paired with L-carnitine supplements can reduce the harmful effects and risks associated with these conditions by lowering toxic metabolite levels.
- Long-term treatment with this diet and supplements showed promising results in reducing markers of oxidative damage in patients, suggesting potential protective effects against further complications, although more research is needed to link oxidative stress directly to patient health outcomes.